Irinotecan - Yakult Honsha

Drug Profile

Irinotecan - Yakult Honsha

Alternative Names: Campotesin; Campto; Camptosar; CPT-11; DQ 2805; IHL-305; Irinotecan hydrochloride; Irinotecan liposome injection; Irinotecan semi-solid matrix; Irinotecan SSM; Irkan; Irnocam; SN 38B11; Topotecin; U 101440E

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yakult Honsha
  • Developer Daiichi Sankyo Company; Pfizer; Sanofi; Yakult Honsha
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Gastrointestinal cancer; Leukaemia; Lung cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Small cell lung cancer; Solid tumours; Uterine cancer
  • Discontinued Mesothelioma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Liposomal)
  • 20 Dec 2013 Launched for Pancreatic cancer (unresectable) in Japan (IV)
  • 20 Dec 2013 Launched for Solid tumours (in children) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top